Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.70 |
| ▸ | EGFR | P00533 | 4/20 | 0.64 |
| ▸ | FLT1 | P17948 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048250 | 0.83 | EGFR (0.51) | KDREGFR | |
| SCHEMBL1460928 | 0.83 | KDR (1.00) | KDREGFR | |
| SCHEMBL5741783 | 0.79 | KDR (0.71) | KDREGFRFLT1FLT4 | |
| SCHEMBL4045525 | 0.79 | KDR (1.00) | KDREGFRFLT1FLT4 | |
| SCHEMBL5739951 | 0.79 | KDR (0.71) | KDREGFRFLT1FLT4 | |
| SCHEMBL1459959 | 0.77 | KDR (0.46) | KDREGFRFLT1FLT4 | |
| SCHEMBL4052014 | 0.77 | KDR (0.77) | KDREGFRFLT1FLT4 | |
| SCHEMBL4048542 | 0.76 | KDR (0.80) | KDREGFRFLT1FLT4 | |
| SCHEMBL4047327 | 0.76 | KDR (0.68) | KDREGFRFLT1FLT4 | |
| SCHEMBL4053446 | 0.75 | KDR (1.00) | KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4649046-B2 | — | — | 2011-03-09 | — | — | JP | claimed |
| EP-1183033-B1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-03-01 | — | — | EP | claimed |
| US-6982265-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-01-03 | — | — | US | claimed |
| JP-2003500359-A | — | — | 2003-01-07 | — | — | JP | claimed |
| EP-1183033-A4 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2002-07-17 | — | — | EP | claimed |
| EP-1183033-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2000071129-A1 | PYRROLOTRIAZINE INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-11-30 | — | — | WO | claimed |
| EP-1562949-B1 | METHODS FOR THE PREPARATION OF PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| EP-1669071-B1 | Pyrrolotriazine inhibitors of kinases | BRISTOL MYERS SQUIBB CO (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1562949-A4 | METHODS FOR THE PREPARATION OF PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7244733-B2 | Pyrrolotriazine inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-7211666-B2 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-20050107462-A1 | N-Cyclopropyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; aminating with chloramine to produce a pyrrole with a Nitrogen nitrogen bond; reacting with formamide, cyclizing to form the pyrrolotriazine core; kinase inhibitors | GODFREY JOLLIE D JR (US) | 2005-05-19 | — | — | US | disclosed |
| US-6867300-B2 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040229877-A1 | Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds | LEFTHERIS KATERINA (US) | 2004-11-18 | — | — | US | disclosed |
| WO-2004043912-A2 | METHODS FOR THE PREPARATION OF PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6670357-B2 | Antiinflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030186982-A1 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069244-A1 | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors | MAPK1, MAPK3, MAPK6 | KDR 3890/4885EGFR 2025/4885FLT1 2942/4885 |
| US-20090227567-A1 | METHODS OF TREATING P38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | MAP3K5, MAPK1, MAPKAPK5 | KDR 3537/4885EGFR 1916/4885FLT1 2305/4885 |
| US-20040229877-A1 | Methods of treating p38 kinase-associated conditions with pyrrolotriazine compounds | MAPK1, MAPK6, MAPK3 | KDR 4348/4885EGFR 2477/4885FLT1 3405/4885 |
| US-20050107462-A1 | N-Cyclopropyl-4-[[5-[(methoxyamino)carbonyl]-2-methylphenyl]amino]-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide; aminating with chloramine to produce a pyrrole with a Nitrogen nitrogen bond; reacting with formamide, cyclizing to form the pyrrolotriazine core; kinase inhibitors | CSNK2A1, CSNK1A1, NEK2 | KDR 1144/4885EGFR 749/4885FLT1 703/4885 |
| US-20030186982-A1 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors | PRKD2, CSNK1A1, CSNK2A1 | KDR 1932/4885EGFR 1248/4885FLT1 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.